Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Ovarian Cancer.

Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Pancreatic Cancer.

Best Stocks for 10 Years. In this article, we are going to take a look at where Bristol-Myers Squibb Co. (NYSE:BMY) stands ...

There are few cities in the UK that bounce to the beat of the night like Bristol, and you can bet that when it comes to New Year's Eve, they aren't planning on doing it any differently.